Comments
Shares of Biocon will remain in focus on Friday, as the company strengthens its presence in Mexico. In a post-market hour disclosure, Biocon said it has received approval from Cofepris, the Mexican health authority, for insulin glargine through its partner PiSA Farmaceutica. Through the tie-up, Biocon will introduce Galactus, the long acting insulin glargine in Mexico, which has a disease prevalence of 12 per cent, the second highest in the world.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.